how-to-patent-in-europe-epo 
The IPKat
DECEMBER 20, 2023
US patent attorneys wishing to understand certain peculiarities of European patent drafting need look no further than the recent Board of Appeal decision in T 2171/21. This case is a textbook example of the EPO's strict approach to added matter. Profanity The patent was opposed for added matter.
The IPKat
MAY 31, 2023
The US Supreme Court recently ruled in the high profile Amgen versus Sanofi patent dispute. 2021 ), the Supreme Court found Amgen's function and epitope defined PCSK9 antibody patents to lack enablement ( Amgen Inc v Sanofi, No. The patents in dispute in Amgen v Sanofi defined a class of antibodies by their function and epitope.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The IPKat
DECEMBER 28, 2021
Following on from our IPKat EBA 2021 Year in Review , here is some more festive holiday reading on some of the important decisions to come out of the EPO Boards of Appeal this year. 2021 saw key decisions on claim supremacy, types of antibody claims, the data threshold for second medical use inventions and the AI inventor debate. ??
Fish & Richardson Trademark & Copyright Thoughts
JUNE 14, 2022
Moritz Ammelburg and Peter Fasse examine the patentability requirements and prosecution schemes in the US and Europe and how applicants can prepare applications that will best serve their needs in both jurisdictions. can significantly complicate the coordination of a global patent strategy. PDF copy available.
The IPKat
JANUARY 24, 2023
This Kat is delighted to review “ A Practitioner’s Guide to European Patent Law: For National Practice and the Unified Patent Court ” (Hart Publishing, 2022, 664 pp.). non-infringement or that a patent is standard essential), and on FRAND (fair, reasonable and non-discriminatory) licensing. the Bolar exemption and exhaustion).
IPilogue
AUGUST 11, 2021
To illustrate, consider how the law taxes activity by a person and a machine differently. As AI continues to improve, it is going to take over an ever-increasing number of tasks that were once only performed by people. This is going to have profound consequences socially, economically, and legally.
SpicyIP
FEBRUARY 4, 2024
In May 2023, the UK Court of Appeal upheld the invalidity of Bristol-Myers Squibb’s Apaxiban patent for lacking “plausibility” But how does this finding interact with the position of relevant laws in India? Amit is a registered Patent Agent and is currently part of IP litigation team at Sun Pharmaceuticals.
Expert insights. Personalized for you.
109 
Let's personalize your content